Long-Term Efficacy & Safety of Aflibercept IVT for the Treatment of DME in Subjects Who Completed the VISTA-DME Trial
Status:
Completed
Trial end date:
2017-01-09
Target enrollment:
Participant gender:
Summary
The Endurance Trial is a phase IV open label clinical study to assess the need for ongoing
intravitreal aflibercept injections after the 3-year VISTA DME (VGFT-OD-1009; NCT01363440)
end-point. Subjects will be treated with intravitreal aflibercept injections pro re nata
(PRN) based on the presence of CR-DME (Clinically Relevant-DME). In addition, subjects who
meet re-treatment criteria will be eligible for focal laser treatment every 90 days.